Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

The estimated patent date of Remicade and Rituxan

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
rwdm Member Profile
 
Followed By 2
Posts 72
Boards Moderated 0
Alias Born 07/19/10
160x600 placeholder
Heineken has agreed to sell its Mexican packaging business to Crown Holdings for $1.23 billion in cash, allowing the Dutch brewer to tighten its focus on beer.
More Top Equities Stories Of The Day
Apple Investigating Reports of iCloud Vulnerabilities
US Court Dismisses Aluminum Antitrust Cases
J.P. Morgan Working With Law Enforcement on Cyber Attack -- 3rd Update
U.S. Hot Stocks: Hot Stocks to Watch
Ex-LPL Broker Ordered to Pay Nearly $2 Million
U.S. Hot Stocks: Hot Stocks to Watch
Amazon, Twitter Gains Lead Techs Higher
Ukraine Tensions Spur U.S. Stock Futures Downward
rwdm   Thursday, 07/29/10 02:07:10 PM
Re: None
Post # of 181585 
The estimated patent date of Remicade and Rituxan in Europe are 2014 and 2015 respectively. In the US both expiry dates are in 2018. Is this because of Genentech's Cabily patent? If yes, does this mean that the expiry date of most of the mabs in US is 2018?

Is Teva's Rituximab TL011, which is starting nowadays clinical trials, in the regulatory pathway of BLA or as a biosimilar?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist